---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-044028"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:50:05.627460+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment

## Summary
- MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.
- Phase 3 LUMEOS trial showed 40% of treated patients improved in ≥2 endpoints vs 0% in control.
- MeiraGTx intends to file BLA and MAA in US, EU, and Japan for bota-vec, targeting potential launch in 2027.
- JJDC, Johnson & Johnson investment arm, owns >5% of MeiraGTx shares and agreed to 12-month lock-up.
- Estimated >20,000 XLRP patients in US and EU, with potential peak market of $1.7B.

## SEC filing metadata
- accession: 0001104659-26-044028
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/0001104659-26-044028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/mgtx-20260415x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-044028
- JSON: https://secwatch.observer/filing/0001104659-26-044028.json
- Plain text: https://secwatch.observer/filing/0001104659-26-044028.txt

## Source-grounded claims
- claim_id: 0ad170235c8e57d7452f31e1bac9849304c10679
  claim: MeiraGTx Holdings plc completed an acquisition involving Janssen Pharmaceuticals, Inc. for upfront cash purchase price of $25,000,000 (closed 2026-04-15).
  evidence_excerpt: to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price of $25,000,000 to Seller. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Buyer agreed to pay Seller a one-time, future contingent
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/0001104659-26-044028-index.htm
- claim_id: 4b159c4859ddfe51e01e7883ef29a2fad8b129b3
  claim: MeiraGTx Holdings plc entered into Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. valued at $25,000,000 (effective 2026-04-15).
  evidence_excerpt: On April 15, 2026 (the “Closing Date”), MeiraGTx Holdings plc (the “Company”) and its wholly-owned subsidiary MeiraGTx Ocular UK Limited, a company incorporated in England and Wales (“MeiraGTx Ocular” and together with the Company, collectively the “Buyer”), entered into and consummated an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Seller”), pursuant to which Seller sold and assigned to Buyer, and Buyer purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) and Janssen (the “UCL License Agreement”), relating to the research, development, manufacture and exploitation of Seller’s gene therapy product for the treatment of X-linked retinitis pigmentosa related to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/0001104659-26-044028-index.htm
- claim_id: d44d09ed6021d245d717d63ee523bd93b5042201
  claim: MeiraGTx Holdings plc terminated Original Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. (effective 2026-04-15).
  evidence_excerpt: Seller and Buyer entered into a Termination Agreement on April 15, 2026 (the “Termination Agreement”) terminating that certain Asset Purchase Agreement, dated as of December 20, 2023 (the “Original Asset Purchase Agreement”), by and among Seller and the Company and its wholly-owned subsidiary MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), that certain Supply Agreement, dated as of December 20, 2023 by and between MeiraGTx UK II and Seller, and certain other documents related to the Original Asset Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/0001104659-26-044028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.